Awareness of polycystic ovary syndrome among obstetrician-gynecologists and endocrinologists in Northern Europe.
Adult
Comorbidity
Contraceptives, Oral
/ therapeutic use
Cross-Sectional Studies
Endocrinologists
/ psychology
Europe
Female
Humans
Life Style
Male
Metformin
/ therapeutic use
Middle Aged
Physicians
/ psychology
Polycystic Ovary Syndrome
/ diagnosis
Psychotherapy
Regression Analysis
Surveys and Questionnaires
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
20
08
2019
accepted:
18
11
2019
entrez:
27
12
2019
pubmed:
27
12
2019
medline:
9
4
2020
Statut:
epublish
Résumé
To date, little is known about differences in the knowledge, diagnosis making and treatment strategies of health care providers regarding polycystic ovary syndrome (PCOS) across different disciplines in countries with similar health care systems. To inform guideline translation, we aimed to study physician reported awareness, diagnosis and management of PCOS and to explore differences between medical disciplines in the Nordic countries and Estonia. This cross-sectional survey was conducted among 382 endocrinologists and obstetrician-gynaecologists in the Nordic countries and Estonia in 2015-2016. Of the participating physicians, 43% resided in Finland, 18% in Denmark, 16% in Norway, 13% in Estonia, and 10% in Sweden or Iceland, and 75% were obstetrician-gynaecologists. Multivariable logistic regression models were run to identify health care provider characteristics for awareness, diagnosis and treatment of PCOS. Clinical features, lifestyle management and comorbidity were commonly recognized in women with PCOS, while impairment in psychosocial wellbeing was not well acknowledged. Over two-thirds of the physicians used the Rotterdam diagnostic criteria for PCOS. Medical endocrinologists more often recommended lifestyle management (OR = 3.6, CI 1.6-8.1) or metformin (OR = 5.0, CI 2.5-10.2), but less frequently OCP (OR = 0.5, CI 0.2-0.9) for non-fertility concerns than general obstetrician-gynaecologists. The physicians aged <35 years were 2.2 times (95% CI 1.1-4.3) more likely than older physicians to recommend lifestyle management for patients with PCOS for fertility concerns. Physicians aged 46-55 years were less likely to recommend oral contraceptive pills (OCP) for patients with PCOS than physicians aged >56 (adjusted odds ratio (OR) = 0.4, 95% CI 0.2-0.8). Despite well-organized healthcare, awareness, diagnosis and management of PCOS is suboptimal, especially in relation to psychosocial comorbidities, among physicians in the Nordic countries and Estonia. Physicians need more education on PCOS and evidence-based information on Rotterdam diagnostic criteria, psychosocial features and treatment of PCOS, with the recently published international PCOS guideline well needed and welcomed.
Identifiants
pubmed: 31877155
doi: 10.1371/journal.pone.0226074
pii: PONE-D-19-23460
pmc: PMC6932801
doi:
Substances chimiques
Contraceptives, Oral
0
Metformin
9100L32L2N
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0226074Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Curr Treat Options Cardiovasc Med. 2011 Aug;13(4):289-301
pubmed: 21562798
Hum Reprod. 2017 May 1;32(5):1075-1091
pubmed: 28333286
J Clin Endocrinol Metab. 2014 Jan;99(1):E107-11
pubmed: 24178791
Health Care Anal. 1999;7(4):321-30
pubmed: 10787795
Semin Reprod Med. 2018 Jan;36(1):19-27
pubmed: 30189447
Hum Reprod. 2018 Sep 1;33(9):1602-1618
pubmed: 30052961
Semin Reprod Med. 2018 Jan;36(1):5-12
pubmed: 30189445
Int J Endocrinol Metab. 2017 Jan 22;15(1):e43695
pubmed: 28835764
Eur J Endocrinol. 2014 Oct;171(4):489-98
pubmed: 25049203
Fertil Steril. 2017 Jun;107(6):1380-1386.e1
pubmed: 28483503
J Family Reprod Health. 2016 Jun;10(2):92-8
pubmed: 27648099
Clin Endocrinol (Oxf). 2018 Dec;89(6):683-699
pubmed: 30099747
Intern Med J. 2014 Aug;44(8):720-6
pubmed: 24909750
Oncotarget. 2017 Jul 12;8(56):96351-96358
pubmed: 29221211
Int J Endocrinol. 2018 Nov 14;2018:7234543
pubmed: 30538744
Hum Reprod Update. 2010 Jul-Aug;16(4):347-63
pubmed: 20159883
Lancet. 2018 Jun 2;391(10136):2236-2271
pubmed: 29893224
Fertil Steril. 2019 Aug;112(2):353-361
pubmed: 31056307
J Clin Endocrinol Metab. 2017 Jun 1;102(6):1861-1869
pubmed: 28323926
Lancet. 2017 Dec 16;390(10113):2627-2642
pubmed: 29029897
Hum Reprod. 2016 Dec;31(12):2841-2855
pubmed: 27664216
Med J Aust. 2018 Oct 1;209(S7):S3-S8
pubmed: 30453865